PQQ (Pyrroloquinoline Quinone) — Research Profile

PQQ and CoQ10 work on different aspects of mitochondrial health. PQQ stimulates mitochondrial biogenesis — the creation of entirely new mitochondria — via PGC-1α activation. CoQ10 supports the function of existing mitochondria as an electron carrier in the energy production chain. Together, they provide comprehensive mitochondrial support: PQQ increases the number of mitochondria while CoQ10 improves their efficiency.

Most clinical studies use 10-20mg daily. The cognitive benefit trial by Itoh et al. used 20mg, which appears to be the optimal dose for most people. There is no strong evidence that higher doses provide additional benefits, and safety data above 20mg is limited. PQQ can be taken with or without food.

PQQ is found in small amounts in kiwifruit, green peppers, parsley, tea, and fermented soybeans (natto). However, dietary intake is typically only 0.1-1mg per day, far below the 10-20mg doses used in clinical studies. Supplementation is necessary to achieve therapeutic levels.

The form with human evidence is oral PQQ disodium salt, marketed as BioPQQ, which is the material used in the 12-week trial that gave 20 mg/day to older adults. No head-to-head comparison of different PQQ forms exists, so the disodium salt at studied doses is the most defensible choice rather than any newer marketed variant.

Evidence is limited and preliminary. A 12-week trial in 41 older adults found 20 mg/day improved selective attention (Stroop) and working memory, mainly in lower-performing participants, and a small human crossover study reported reduced plasma C-reactive protein and IL-6 alongside urinary markers of enhanced mitochondrial function. The widely cited mitochondrial-biogenesis effect via CREB and PGC-1alpha has so far been demonstrated only in cells, not in humans.

Human trials have used 20 mg/day, which is both the dose in the 12-week cognition study and the intake EFSA reviewed as safe for adults. The human inflammation study instead used weight-based dosing of 0.2 to 0.3 mg/kg, roughly 14 to 21 mg for a 70 kg adult. No official standardized dose is established, but 20 mg/day reflects where the evidence sits.

Trials gave PQQ once daily but never compared morning versus evening dosing, so no optimal time of day has been established. Because the measured effects on attention and mitochondrial markers accumulate over weeks rather than appearing acutely, the specific hour you take it has not been shown to matter.

The 12-week cognition trial at 20 mg/day reported no adverse effects, and EFSA's review raised no safety concerns at that intake for healthy adults. Because human data come only from small, short trials, uncommon or longer-term side effects may not yet have been captured.

No specific drug interactions for PQQ have been documented in human trials, and EFSA's safety review did not identify any medication interactions. That reflects an absence of interaction data rather than proven safety, so anyone on prescription medication should regard combined use as untested.

The human evidence centers on older adults with age-related decline in attention and memory, where 20 mg/day produced a modest benefit. EFSA limits its safety conclusion to healthy adults and specifically excludes pregnant and lactating women. Overall the evidence is too preliminary to recommend PQQ broadly.

The main controlled trial gave 20 mg/day for 12 weeks before measuring gains in attention and working memory, so PQQ is studied as a multi-week regimen rather than an acute-effect supplement. No study has mapped a faster onset for supplemental PQQ, and in that trial the benefit was clearest in participants who started with lower cognitive scores.

Published human trials have only run up to about 12 weeks at 20 mg/day with no adverse effects reported, so genuinely long-term safety in people is not established. EFSA reviewed BioPQQ disodium salt and judged 20 mg/day safe for healthy adults, excluding pregnant and lactating women, based on a 90-day rat no-adverse-effect level of 100 mg/kg body weight per day.

No tolerable upper limit has been set for humans. EFSA's assessment rested on a 90-day rat no-observed-adverse-effect level of 100 mg/kg body weight per day and concluded that the marketed 20 mg/day intake carries a margin of exposure of 344. Human trials have not tested doses above roughly 20 mg/day, so the safety of higher intakes is simply unknown.

No human trials have tested PQQ combined with other supplements for added benefit, so any pairing is unproven. Cell studies show PQQ drives mitochondrial biogenesis through CREB and PGC-1alpha, which is the rationale often given for stacking it with CoQ10, but that specific combination has not been validated in controlled human studies.

Most clinical evidence used BioPQQ, a pyrroloquinoline quinone disodium salt produced by fermentation (Hyphomicrobium denitrificans) at a minimum purity of 99%, dosed at 20 mg/day. Look for the disodium salt form at a 20 mg dose that matches the trials, plus third-party purity testing rather than proprietary blends that hide the actual PQQ amount.